ACTRN12615000920594已完成未知
A randomised double blinded placebo controlled study investigating Atopis for the improvement of skin health in subjects with eczema
Decima Health Ltd0 个研究点目标入组 60 人开始时间: 2015年9月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 16 Years 至 70 Years(—)
- 性别
- All
入选标准
- •1.Healthy male or female between 16 and 70 years of age.
- •2.Subjects with mild to moderate eczema; which will be determined using the Eichenfield Revised Criteria of Hannafin and Rajka at screening visit.
- •3.Judged by the Investigator to be in general good health on the basis of medical history.
- •4.Agree to use the Study-supplied investigational product as the only body cosmetic applied to irritated skin.
- •5.Agree to stop all dietary supplements including probiotics, dermatological medications and creams for eczema, during the entire length of the study
- •6.Agree not to change their current diet or exercise program during the entire study period.
- •7.Understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator.
- •8. Females of child bearing potential must agree to use appropriate birth control methods during the entire study period.
排除标准
- •a)Clinically significant renal, hepatic, endocrine (including diabetes mellitus), cardiac, pulmonary, pancreatic, neurologic, hematologic, or biliary disorder.
- •b)Known allergy or sensitivity to Herbal products
- •c)Use of systemic corticosteroids in the past 30 days.
- •d)History of malignancy in the past two years.
- •e)Recent history of alcoholism (within 12 months) or strong potential for alcohol or substance abuse.
- •f)Participation in a clinical study with exposure to any non-registered drug product within 30 days prior.
- •g)Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, to comply with the study protocol or which might confound the interpretation of the study results or put the person at undue risk. Including subjects who are bed or wheelchair-bound.
- •h)Pregnant or lactating during the duration of the study.
- •i)Smoking – must be nonsmoker for at least 12 months prior to screening.
研究者
相似试验
已完成
3 期
Rituximab in patients with primary Sjögren's syndromeISRCTN65360827niversity of Leeds (UK)110
已完成
2 期
A randomised double blind placebo controlled clinical trial of the efficacy of an Australian naltrexone implant compared to oral naltrexone for the long-term management of heroin-dependent personsHeroin dependenceMental Health - AddictionACTRN12606000308594niversity of Western Australia70
进行中(未招募)
不适用
A clinical trial to show whether there is an improvment in symptoms after the administration of rituximab in patients with primary Sjögren’s syndrome.Primary Sjögren’s syndrome (PSS).MedDRA version: 14.1Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-021430-64-GBniversity of Leeds110
已完成
不适用
A clinical trial to evaluate effects of Misoprostol by sublingual route after delivery of neonate in preventing postpatum bleeding in comparison to intramuscular injection of oxytocin.CTRI/2009/091/000672Chittaranjan Sevasadan HospitalSPMukherjee RoadKolkata600
已完成
2 期
Clinical and physiological evaluation of a Chinese herbal medicine for constipation-predominant Irritable Bowel Syndrome (C-IBS Trial).Constipation-predominant Irritable Bowel SyndromeAlternative and Complementary Medicine - Herbal remediesACTRN12609000558224niversity of Western Sydney160
